|

BP1001-A (Liposomal Grb2 Antisense Oligonucleotide) Clinical Trials

1 actively recruiting trial across 1 location

Pipeline

Phase 1: 1

Top Sponsors

  • Bio-Path Holdings, Inc.1

Indications

  • Carcinoma, Ovarian Epithelial1
  • Peritoneal Cancer1
  • Fallopian Tube Neoplasms1
  • Endometrial Cancer1
  • Solid Tumor1

Silver Spring, Maryland1 trial

BP1001-A in Patients With Advanced or Recurrent Solid Tumors

Holy Cross Hospital

Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.